Overview of Clomiphene Citrate Use in Male Hypogonadism and Infertility

Abstract

Listen

Translate article

Clomiphene Citrate (CC) has been widely used in medicine since the 1970s, primarily as a Selective Estrogen Receptor Modulator (SERM) for female ovulation induction. However, its off-label use in men has gained traction, particularly for the treatment of hypogonadotropic hypogonadism and idiopathic infertility. CC’s mechanism of action, which increases gonadotropin-releasing hormone (GnRH) secretion and subsequently elevates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, offers a unique advantage by preserving the hypothalamic-pituitary-gonadal axis and maintaining fertility. This article presents evidence supporting CC’s efficacy and safety in these contexts, summarizing data from systematic reviews, meta-analyses, and retrospective studies. In hypogonadotropic men, CC has been shown to significantly improve total and free testosterone levels, gonadotropin concentrations, and hypogonadism symptoms, while avoiding common complications of testosterone replacement therapy (TRT), such as secondary polycythemia. CC also demonstrated favorable outcomes in seminal parameters, including sperm concentration and motility, as well as improved pregnancy rates in idiopathic infertility cases. Adverse effects reported with CC use include reduced energy, mood instability, and occasional visual disturbances, most of which are mild and reversible. Long-term safety data are reassuring, with rare severe adverse events such as thrombotic complications. Studies comparing CC to TRT indicate a lower risk of hematological and prostate-related complications, underscoring its safety profile. While the evidence supports CC as a viable alternative or adjunct to TRT in specific patient populations, further research is needed to refine treatment protocols, assess long-term outcomes, and explore biofunctional sperm parameters. Overall, CC represents a promising, cost-effective therapeutic option for addressing male hypogonadism and infertility, with its integration into clinical practice guided by careful patient selection and ongoing monitoring.